Genomic DNA at disease-causing loci (gDNA)

Genomic DNA at disease-causing loci represents the specific segments of the human genome where mutations or structural variations lead to clinical pathology (National Human Genome Research Institute, 2024). These loci serve as the primary blueprint for cellular function, and their precise sequence determines the expression and structure of all proteins within an organism. Unlike traditional small molecules that target proteins, gene-editing therapeutics like CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), and TALENs are designed to directly interact with these DNA sequences to effect permanent changes (Doudna & Charpentier, 2014). By facilitating site-specific modifications—such as the correction of point mutations in sickle cell disease or the disruption of the BCL11A enhancer—these interventions aim to provide curative outcomes for previously intractable genetic disorders (FDA, 2023). The therapeutic potential of targeting genomic DNA is vast, spanning oncology, rare hereditary diseases, and chronic viral infections. However, the clinical application is constrained by the risk of off-target effects, where unintended genomic regions are modified, potentially leading to genomic instability or secondary malignancies (Zhang et al., 2015).

Other names

Genomic DNAChromosomal DNATarget DNA sequenceGenetic lociDisease-associated alleles

Site-specific DNA modification including double-strand break induction followed by cellular repair (NHEJ or HDR), base editing, and prime editing to correct or disrupt pathogenic sequences (Knott & Doudna, 2018).